within Pharmacolibrary.Drugs.ATC.L;

model L01EG01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00027,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.162,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0777,
    k12             = 53.9,
    k21             = 53.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EG01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Temsirolimus is an mTOR inhibitor used primarily in the treatment of advanced renal cell carcinoma. It is also studied for other malignancies. Temsirolimus is approved for clinical use and is administered intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in adult patients with advanced cancer following intravenous administration of 25 mg temsirolimus. Parameters are based on population PK modeling.</p><h4>References</h4><ol><li><p>Boni, JP, et al., &amp; Sonnichsen, D (2009). Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. <i>Seminars in oncology</i> 36 Suppl 3 S18–S25. DOI:<a href=\"https://doi.org/10.1053/j.seminoncol.2009.10.009\">10.1053/j.seminoncol.2009.10.009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19963096/\">https://pubmed.ncbi.nlm.nih.gov/19963096</a></p></li><li><p>Boni, JP, et al., &amp; Hug, B (2008). Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. <i>British journal of cancer</i> 98(11) 1797–1802. DOI:<a href=\"https://doi.org/10.1038/sj.bjc.6604376\">10.1038/sj.bjc.6604376</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18458675/\">https://pubmed.ncbi.nlm.nih.gov/18458675</a></p></li><li><p>Mbatchi, LC, et al., &amp; Houede, N (2017). Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. <i>Cancer chemotherapy and pharmacology</i> 80(3) 653–659. DOI:<a href=\"https://doi.org/10.1007/s00280-017-3379-5\">10.1007/s00280-017-3379-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28676933/\">https://pubmed.ncbi.nlm.nih.gov/28676933</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EG01;
